Claims
- 1. A method of down-regulating the immune response in a human being suffering from an inflammatory condition mediated by a hyperimmune response resulting from cytokine release and receptor expression by immune and non-immune cells, interleukin1 (IL-1) or IL-1 and interleukin-2 (IL-2) release from interleukin-1 and interleukin-2 releasing cells, which comprises administering thereto an immunosuppressive amount of calcitonin gene-related peptide (CGRP) effective to down-regulate the immune response and ameliorate the inflammatory condition.
- 2. A method according to claim 1, wherein the CGRP is administered by injection.
- 3. A method according to claim 2, wherein the injection is intramuscular.
- 4. A method according to claim 1, wherein the inflammatory condition is a chronic inflammatory disease.
- 5. A method according to claim 4, wherein the disease is rheumatoid arthritis.
- 6. A sterile pharmaceutical composition adapted for systemic administration by injection which comprises per unit dosage an IL-1 release inhibiting amount of CGRP from 10 to 100 mg per unit dosage, in admixture with a pharmaceutically acceptable carrier.
- 7. The method of claim 1, wherein an amount from 10 to 100 mg per unit dose of CGRT is administered thereto.
- 8. A method of treating diabetes which comprises administering to a human being suffering from the disease an immunosuppressive amount of calcitonin gene-related peptide (CGRP) effective to ameliorate the disease.
- 9. The method of claim 8, wherein an amount from 10 to 100 mg per unit dose of CGRP is administered thereto.
Parent Case Info
This is a continuation, of application Ser. No. 07/408,573 filed Sept. 18, 1989 and now abandoned.
Non-Patent Literature Citations (1)
Entry |
Nong et al. "Peptides Encoded by the Calcitonin Gene Inhibit Macrophase Function", J. Immun., 143, 45-49 (Saly 1989). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
408573 |
Sep 1989 |
|